This can largely be attributed to a loss of exclusivity for their multiple myeloma drug Revlimid (lenalidomide)
Retatrutide is available in Canada through research peptide suppliers for research purposes
MT1 appears to be the top option for researchers looking to investigate the potential of melanocortin agonists for [5, 9, 10, 16]: Sunless tanning Reducing the risk of sunburn Increasing tolerance to UV/sunlight Reducing inflammation That is because MT1 has considerably higher selectivity towards MC1R, whose activation is the primary factor that mediates the aforementioned effects
Early human data and practitioner-reported experience have linked this mechanism to potential downstream effects on body composition, lean muscle, and recovery, though evidence for hard clinical outcomes in healthy adults remains mixed and limited, and these associations should not be interpreted as established effects
Some individuals may adjust their dose up or down based on side effect tolerance or diminishing effectiveness, a modification your healthcare provider can guide